Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
EssilorLuxottica Bets on AI-Powered Smart Glasses as Competition Intensifies 
GameStop Misses Q3 Revenue Estimates as Digital Shift Pressures Growth 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
Nvidia Develops New Location-Verification Technology for AI Chips 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Samsung SDI Secures Major LFP Battery Supply Deal in the U.S. 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
SAN DIEGO, Nov. 08, 2017 -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced that the company will participate in the Stifel 2017 Healthcare Conference in New York, NY.
The Company will be presenting at 9:30 AM Eastern on Wednesday, November 15, 2017. A live webcast of the presentation will be available on the Investor Relations page of the Company's website at: http://ir.vitaltherapies.com/. An archive of the presentation will be available for replay following the conference.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company’s ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
Contact:
Vital Therapies, Inc.
Al Kildani
Vice President, Investor Relations and Business Development
858-673-6840
[email protected]
